Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development

/PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the...

Related Keywords

China ,Taian ,Shandong ,Taipei ,T Ai Pei ,Taiwan ,Joe Hsueh ,Joe Shih ,Angus Wu ,China Development Industrial Bank ,Business Development ,National Development Fund Business Angel Investment Program ,National Research Program For Biopharmaceuticals ,Taian Venture Capital ,National Development Fund ,Business Angel Investment Program ,Implementation Project ,Strengthening Investment ,National Research Program ,Tsu An Hsu ,General Manager ,Next Generation Sequencing ,Media Inquiries ,Please Contact ,Anbogen Therapeutics ,